Drug Research
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize...
Samsung Bioepis Co., Ltd. announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar...
Drug Research
Pathios Therapeutics and Sygnature Discovery sign strategic partnership
Pathios Therapeutics, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery have announced a strategic...
Drug Research
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling...
Drug Research
IDDI starts Collaborative Research on Ground-Breaking Statistical Method for...
The treatment of patients in clinical practice relies on the results of randomized clinical trials. The statistical methods currently used to test the treatment effects...
Drug Research
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene...
Kyn Therapeutics, a clinical-stage biotechnology company advancing research into new immunometabolic therapies for treating cancer, announced it has entered into a global strategic collaboration with...
Drug Research
Branched-Chain Amino Acids Found to Regulate the Development and...
Researchers at A*STAR's Singapore Bioimaging Consortium (SBIC) have discovered that branched-chain amino acids (BCAAs) in tumours can be targeted to prevent and treat cancer. ...
Drug Research
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and...
Regeneron Pharmaceuticals, Inc. and Sanofi have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.